Business, energy, technology, markets and global industry news from Business News Today

polycythemia vera

PharmaDeviceNews polycythemia vera
Silence Therapeutics’ $175 million public offering strengthens its funding position as divesiran advances toward planned Phase 3 development in polycythemia vera. Representative image.
Pharma & Biotech

Silence Therapeutics raised $175m right after SANRECO success. What does it unlock for divesiran?

Silence Therapeutics raises $175 million after positive divesiran Phase 2 data, strengthening funding ahead of a planned Phase 3 PV trial.

Read More
Silence Therapeutics approaches a key Phase 2 SANRECO trial readout for divesiran in polycythemia vera, with investors and clinicians watching hematocrit control, phlebotomy reduction and the potential of infrequent RNA interference therapy. Representative image.
Pharma & Biotech

What will Silence Therapeutics’ SANRECO Phase 2 results reveal about divesiran in polycythemia vera?

Silence Therapeutics will reveal Phase 2 SANRECO divesiran results in polycythemia vera, testing hematocrit control and phlebotomy reduction.

Read More
Pharma & Biotech

PharmaEssentia wins Health Canada approval for BESREMi in polycythemia vera

Read how Health Canada’s BESREMi approval could reshape polycythemia vera treatment, reimbursement and PharmaEssentia’s Canadian strategy.

Read More
Representative image: An unbranded prefilled injection pen and blood samples illustrate PharmaEssentia’s FDA-approved BESREMi Pen launch for polycythemia vera treatment in the United States.
Pharma & Biotech

FDA approves BESREMi Pen as PharmaEssentia targets easier long-term polycythemia vera treatment

FDA approval brings BESREMi Pen to U.S. polycythemia vera care. Find out how convenience, safety and access may shape adoption.

Read More
Representative image: A hematology researcher reviews blood sample data in a clinical laboratory, reflecting PharmaEssentia’s new ropeginterferon alfa-2b evidence in essential thrombocythemia ahead of ASCO 2026 and EHA 2026.
Pharma & Biotech

Can PharmaEssentia turn ropeginterferon into a broader myeloproliferative neoplasm franchise?

PharmaEssentia’s ET data arrive before a key FDA date. Ropeginterferon could shift timing, sequencing, and risk thinking in MPN care.

Read More
Representative image: A hematology clinician reviews treatment data in a clinical lab setting as Incyte’s FDA approval of once-daily Jakafi XR highlights the next phase of ruxolitinib therapy for myelofibrosis, polycythemia vera and graft-versus-host disease.
Pharma & Biotech

Can Jakafi XR defend Incyte’s ruxolitinib franchise as dosing convenience becomes strategic?

Jakafi is mature, but dosing still matters. Incyte’s Jakafi XR approval could extend ruxolitinib’s strategic life in hematology.

Read More
Pharma & Biotech

PharmaEssentia expands beyond Taiwan with Puerto Rico plant as BESREMi growth plans widen

PharmaEssentia’s Puerto Rico facility could reshape BESREMi supply resilience and U.S. expansion. Read what this means for biologics strategy.

Read More
What epetraborole’s hematocrit effects could mean for the future treatment landscape in polycythemia veraWhat epetraborole’s hematocrit effects could mean for the future treatment landscape in polycythemia vera
Pharma & Biotech

Can AN2 Therapeutics reposition epetraborole for polycythemia vera and reshape hematocrit control strategies?

AN2 Therapeutics plans a Phase 2 trial of epetraborole for polycythemia vera. Explore what this strategy could mean for future hematology treatments.

Read More
Pharma & Biotech

PharmaEssentia Corporation secures Japan approval for high-dose BESREMi regimen in polycythemia vera

Japan approves high-dose BESREMi regimen for polycythemia vera. Read the full analysis on safety, adoption, and what clinicians will watch next.

Read More
Pharma & Biotech

Takeda and Protagonist near FDA decision on novel PV therapy rusfertide

FDA grants Priority Review to rusfertide for polycythemia vera. Discover what this means for treatment standards and market dynamics.

Read More